These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 19558190)

  • 21. The potential cost-effectiveness of amblyopia screening programs.
    Rein DB; Wittenborn JS; Zhang X; Song M; Saaddine JB;
    J Pediatr Ophthalmol Strabismus; 2012; 49(3):146-55; quiz 145, 156. PubMed ID: 21877675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic evaluations of vision screening to detect amblyopia and refractive errors in children: a systematic review.
    Asare AO; Wong AMF; Maurer D; Kulandaivelu Y; Saunders N; Ungar WJ
    Can J Public Health; 2022 Apr; 113(2):297-311. PubMed ID: 34755325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-utility analysis of orthoptic screening in kindergarten: a Markov model based on data from Germany.
    König HH; Barry JC
    Pediatrics; 2004 Feb; 113(2):e95-108. PubMed ID: 14754978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Informing disinvestment through cost-effectiveness modelling: is lack of data a surmountable barrier?
    Karnon J; Carlton J; Czoski-Murray C; Smith K
    Appl Health Econ Health Policy; 2009; 7(1):1-9. PubMed ID: 19558190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical effectiveness and cost-effectiveness of screening programmes for amblyopia and strabismus in children up to the age of 4-5 years: a systematic review and economic evaluation.
    Carlton J; Karnon J; Czoski-Murray C; Smith KJ; Marr J
    Health Technol Assess; 2008 Jun; 12(25):iii, xi-194. PubMed ID: 18513466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustainability in Health care by Allocating Resources Effectively (SHARE) 2: identifying opportunities for disinvestment in a local healthcare setting.
    Harris C; Allen K; King R; Ramsey W; Kelly C; Thiagarajan M
    BMC Health Serv Res; 2017 May; 17(1):328. PubMed ID: 28476159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Case studies that illustrate disinvestment and resource allocation decision-making processes in health care: a systematic review.
    Polisena J; Clifford T; Elshaug AG; Mitton C; Russell E; Skidmore B
    Int J Technol Assess Health Care; 2013 Apr; 29(2):174-84. PubMed ID: 23514665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Büyükkaramikli NC; Blommestein HM; Riemsma R; Armstrong N; Clay FJ; Ross J; Worthy G; Severens J; Kleijnen J; Al MJ
    Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel research design can aid disinvestment from existing health technologies with uncertain effectiveness, cost-effectiveness, and/or safety.
    Haines T; O'Brien L; McDermott F; Markham D; Mitchell D; Watterson D; Skinner E
    J Clin Epidemiol; 2014 Feb; 67(2):144-51. PubMed ID: 24275500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level.
    Calabrò GE; La Torre G; de Waure C; Villari P; Federici A; Ricciardi W; Specchia ML
    BMC Health Serv Res; 2018 Mar; 18(1):148. PubMed ID: 29490647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generalisability in economic evaluation studies in healthcare: a review and case studies.
    Sculpher MJ; Pang FS; Manca A; Drummond MF; Golder S; Urdahl H; Davies LM; Eastwood A
    Health Technol Assess; 2004 Dec; 8(49):iii-iv, 1-192. PubMed ID: 15544708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of NICE technology appraisal in NHS rationing.
    Walker S; Palmer S; Sculpher M
    Br Med Bull; 2007; 81-82():51-64. PubMed ID: 17409119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
    Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical effectiveness and cost-effectiveness of technologies used to visualise the seizure focus in people with refractory epilepsy being considered for surgery: a systematic review and decision-analytical model.
    Burch J; Hinde S; Palmer S; Beyer F; Minton J; Marson A; Wieshmann U; Woolacott N; Soares M
    Health Technol Assess; 2012; 16(34):1-157, iii-iv. PubMed ID: 22985954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Pandor A; Stevenson M; Stevens J; James MM; Hamilton J; Byrne J; Rudin C; Rawdin A; Wong R
    Pharmacoeconomics; 2018 Aug; 36(8):903-915. PubMed ID: 29480454
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.